Biomarkers and Lung Cancer: Clinical Application

Dear Colleagues,

Lung cancer is the leading cause of cancer-related mortality worldwide. The five-year survival rate is strongly associated with late diagnosis (23% for stage III–IV vs. 67% for the early stages).

Screening programs based on low-dose computed tomography (LD-CT) determined a 20% reduction in lung cancer mortality. However, it is not very suitable as a screening test for the mass population due to its high costs, radiation, and false positive rate. Thus, early diagnosis is essential for its therapeutic and prognostic implications. In this scenario, the absence of a non-invasive and inexpensive screening tool is the main issue for the population, particularly for high-risk subjects. Consequently, the discovery of lung cancer biomarkers in body fluids such as blood, urine, stool, saliva, sputum and breath could play a key role in the diagnosis, prognosis and treatment of lung cancer.

The goal of this Special Issue is to share new knowledge about the latest biomolecules and techniques available for minimally invasive screening of lung cancer as well as the critical limitations that require future improvement in order to upgrade the diagnosis, prognosis and treatment of lung cancer patients.

We will include clinically oriented research papers and reviews, with a strong focus on the topics of early diagnosis of lung cancer and biomarkers.

We hope this Special Issue will be of interest to you, and we look forward to receiving your contributions.

Dr. Roberto Gasparri
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.